Document Detail


Release of 6-keto-PGF1 alpha and thromboxane B2 in late appearing cardioprotection induced by the stable PGI analogue: 7-OXO-PGI.
MedLine Citation:
PMID:  8455575     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We have shown earlier that prostacyclin (PGI2) and its stable analogue: 7-oxo-prostacyclin(7-OXO) may induce a prolonged, late appearing (24-48 h after drug administration), dose dependent protection of the heart from harmful consequences of a subsequent severe ischaemic stress, such as myocardial ischaemia, life-threatening ventricular arrhythmias and early ischaemic morphological changes. In an other study we observed that a similar but shortlived (less than 1 h) cardioprotection, induced by 'preconditioning' brief coronary artery occlusions, is greatly reduced by blockade of the cyclooxygenase pathway, suggesting that prostanoids might play a role in this shortlasting protection. Objective of our present study was to elucidate the importance of some arachidonic acid (AA) metabolites, such as PGI2 and thromboxane A2 (TXA2) in the mechanism of the late appearing, prolonged cardioprotection. Estimation of the metabolites: 6-keto-PGF1 alpha (6-KETO) and thromboxane B2 (TXB2) was made from the perfusate of isolated Langendorff hearts of guinea-pigs pretreated with 50 micrograms/kg 7-OXO, 24 and 48 h before preparation. Pretreatment alone produced a slight, but significant elevation of 6-KETO (from 206 +/- 11 to 284 +/- 19 pg/ml/min after 24 h, and to 261 +/- 18 pg/ml/min after 48 h). No change was seen in TXB2 production. Global ischaemia for 25 min (followed by 25 min reperfusion) markedly increased the release of both AA metabolites; maximal values were observed in the third min of reperfusion (6-KETO from 206 +/- 11 to 1275 +/- 55 pg/ml/min and TXB2 from 29 +/- 4 to 172 +/- 12 pg/ml/min).(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
L Szekeres; A Tósaki
Related Documents :
8986855 - Safety and effectiveness of exercise training in patients with silent myocardial ischemia.
8070485 - Metabolic effects of propionate, hexanoate and propionylcarnitine in normoxia, ischaemi...
10355425 - Reduced neutrophil infiltration protects against lung reperfusion injury after transpla...
16908285 - Threshold level of nf-kb activation in small bowel ischemic preconditioning procedure.
2030835 - 1990 mary j. nielubowicz award winner. observations on stress reactions as seen in nava...
2906865 - Xamoterol. a preliminary review of its pharmacodynamic and pharmacokinetic properties, ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Molecular and cellular biochemistry     Volume:  119     ISSN:  0300-8177     ISO Abbreviation:  Mol. Cell. Biochem.     Publication Date:  1993 Feb 
Date Detail:
Created Date:  1993-04-20     Completed Date:  1993-04-20     Revised Date:  2003-11-14    
Medline Journal Info:
Nlm Unique ID:  0364456     Medline TA:  Mol Cell Biochem     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  129-32     Citation Subset:  IM    
Affiliation:
Institute of Pharmacology, Albert Szent-Györgyi Medical University, Szeged, Hungary.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
6-Ketoprostaglandin F1 alpha / metabolism*
Animals
Epoprostenol / analogs & derivatives*,  metabolism,  pharmacology
Guinea Pigs
Heart / drug effects*
Male
Myocardial Ischemia / drug therapy*,  prevention & control
Thromboxane A2 / metabolism
Thromboxane B2 / metabolism*
Chemical
Reg. No./Substance:
35121-78-9/Epoprostenol; 54397-85-2/Thromboxane B2; 57576-52-0/Thromboxane A2; 58962-34-8/6-Ketoprostaglandin F1 alpha; 79821-50-4/7-oxoprostaglandin I2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  31P-NMR magnetization transfer study of reperfused rat heart.
Next Document:  Cardioprotective actions of wild garlic (allium ursinum) in ischemia and reperfusion.